A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

Usha Sunkara, Janet R. Walczak, Lori Summerson, Theresa Rogers, Mario Eisenberger, Samuel R Denmeade, Roberto Pili, Carol Ann Huff, Victoria Sinibaldi, Michael A Carducci

Research output: Contribution to journalArticle

Abstract

The combination of temozolomide (TEM) and interferon-α (IFN-α) previously demonstrated a 30% response rate in metastatic melanoma. A single institution, phase II trial evaluating the efficacy of TEM/IFN in patients with advanced renal cell carcinoma (RCC) was conducted. Safety and tumor response were the main outcomes. Eligible patients received 200 mg/m2/day TEM orally on days 1-5 every 28 days, with IFN 2.5 million U/m2/day subcutaneously (s.c.) three alternate days/week for days 1-15 first cycle, then 5 million U/m2/day s.c. 3 alternate days/week throughout each 28-day cycle. Efficacy was evaluated every 8 weeks, and dose-limiting toxicities (DLTs) were treated with dose reductions of the culprit drug. Sixteen patients (ages 37-67) were initially enrolled. Of the 14 evaluable patients, there was one minor response. Best response was stable disease, with 7 patients remaining on study for ≥6 months. Five were alive for more than 2 years, and 2 remain alive at 45 and 50 months after enrollment. DLTs included TEM-induced myelosuppression and IFN-induced fever/chills. Other toxicities were mild to moderate (grades 1-3). The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease ≥6 months remain of interest.

Original languageEnglish (US)
Pages (from-to)37-41
Number of pages5
JournalJournal of Interferon and Cytokine Research
Volume24
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

temozolomide
Renal Cell Carcinoma
Interferons
Chills
Melanoma
Fever

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma. / Sunkara, Usha; Walczak, Janet R.; Summerson, Lori; Rogers, Theresa; Eisenberger, Mario; Denmeade, Samuel R; Pili, Roberto; Huff, Carol Ann; Sinibaldi, Victoria; Carducci, Michael A.

In: Journal of Interferon and Cytokine Research, Vol. 24, No. 1, 01.2004, p. 37-41.

Research output: Contribution to journalArticle

@article{1cff673d2f0f479ba47fb3a280b831ab,
title = "A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma",
abstract = "The combination of temozolomide (TEM) and interferon-α (IFN-α) previously demonstrated a 30{\%} response rate in metastatic melanoma. A single institution, phase II trial evaluating the efficacy of TEM/IFN in patients with advanced renal cell carcinoma (RCC) was conducted. Safety and tumor response were the main outcomes. Eligible patients received 200 mg/m2/day TEM orally on days 1-5 every 28 days, with IFN 2.5 million U/m2/day subcutaneously (s.c.) three alternate days/week for days 1-15 first cycle, then 5 million U/m2/day s.c. 3 alternate days/week throughout each 28-day cycle. Efficacy was evaluated every 8 weeks, and dose-limiting toxicities (DLTs) were treated with dose reductions of the culprit drug. Sixteen patients (ages 37-67) were initially enrolled. Of the 14 evaluable patients, there was one minor response. Best response was stable disease, with 7 patients remaining on study for ≥6 months. Five were alive for more than 2 years, and 2 remain alive at 45 and 50 months after enrollment. DLTs included TEM-induced myelosuppression and IFN-induced fever/chills. Other toxicities were mild to moderate (grades 1-3). The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease ≥6 months remain of interest.",
author = "Usha Sunkara and Walczak, {Janet R.} and Lori Summerson and Theresa Rogers and Mario Eisenberger and Denmeade, {Samuel R} and Roberto Pili and Huff, {Carol Ann} and Victoria Sinibaldi and Carducci, {Michael A}",
year = "2004",
month = "1",
doi = "10.1089/107999004772719891",
language = "English (US)",
volume = "24",
pages = "37--41",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

AU - Sunkara, Usha

AU - Walczak, Janet R.

AU - Summerson, Lori

AU - Rogers, Theresa

AU - Eisenberger, Mario

AU - Denmeade, Samuel R

AU - Pili, Roberto

AU - Huff, Carol Ann

AU - Sinibaldi, Victoria

AU - Carducci, Michael A

PY - 2004/1

Y1 - 2004/1

N2 - The combination of temozolomide (TEM) and interferon-α (IFN-α) previously demonstrated a 30% response rate in metastatic melanoma. A single institution, phase II trial evaluating the efficacy of TEM/IFN in patients with advanced renal cell carcinoma (RCC) was conducted. Safety and tumor response were the main outcomes. Eligible patients received 200 mg/m2/day TEM orally on days 1-5 every 28 days, with IFN 2.5 million U/m2/day subcutaneously (s.c.) three alternate days/week for days 1-15 first cycle, then 5 million U/m2/day s.c. 3 alternate days/week throughout each 28-day cycle. Efficacy was evaluated every 8 weeks, and dose-limiting toxicities (DLTs) were treated with dose reductions of the culprit drug. Sixteen patients (ages 37-67) were initially enrolled. Of the 14 evaluable patients, there was one minor response. Best response was stable disease, with 7 patients remaining on study for ≥6 months. Five were alive for more than 2 years, and 2 remain alive at 45 and 50 months after enrollment. DLTs included TEM-induced myelosuppression and IFN-induced fever/chills. Other toxicities were mild to moderate (grades 1-3). The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease ≥6 months remain of interest.

AB - The combination of temozolomide (TEM) and interferon-α (IFN-α) previously demonstrated a 30% response rate in metastatic melanoma. A single institution, phase II trial evaluating the efficacy of TEM/IFN in patients with advanced renal cell carcinoma (RCC) was conducted. Safety and tumor response were the main outcomes. Eligible patients received 200 mg/m2/day TEM orally on days 1-5 every 28 days, with IFN 2.5 million U/m2/day subcutaneously (s.c.) three alternate days/week for days 1-15 first cycle, then 5 million U/m2/day s.c. 3 alternate days/week throughout each 28-day cycle. Efficacy was evaluated every 8 weeks, and dose-limiting toxicities (DLTs) were treated with dose reductions of the culprit drug. Sixteen patients (ages 37-67) were initially enrolled. Of the 14 evaluable patients, there was one minor response. Best response was stable disease, with 7 patients remaining on study for ≥6 months. Five were alive for more than 2 years, and 2 remain alive at 45 and 50 months after enrollment. DLTs included TEM-induced myelosuppression and IFN-induced fever/chills. Other toxicities were mild to moderate (grades 1-3). The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease ≥6 months remain of interest.

UR - http://www.scopus.com/inward/record.url?scp=9144222966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144222966&partnerID=8YFLogxK

U2 - 10.1089/107999004772719891

DO - 10.1089/107999004772719891

M3 - Article

VL - 24

SP - 37

EP - 41

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 1

ER -